Loading…
Company attempts another FDA nod after significant personnel change.
Replimune Group, Inc. (Nasdaq: REPL) has initiated a third attempt to secure FDA approval for its product, following the recent departure of Dr. Martin Makary from the company. The departure occurred amid ongoing regulatory efforts.
No specific amounts, filings, or comparators were provided in the announcement. The company's free float stands at 76,229,785 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.